Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 21, 2010

Ipsen to Pay Inspiration $344M in Funding and Equity Investment as Part of Hemophilia Alliance

  • Ipsen is to provide Inspiration Biopharmaceuticals with up to $259 million in funding as part of the companies’ strategic partnership to develop Inspiration’s hemophilia products. The deal will also see Ipsen pay $85 million up front for a 20% stake in Inspiration.

    Additionally, Ipsen will grant Inspiration an exclusive, worldwide sublicense to the recombinant porcine factor VIII product OBI-1, in exchange for $50 million in convertible notes and a 27.5% royalty on future OBI-1 sales.

    The successful development of OBI-1 and Inspirations lead candidate could earn Inspiration another $174 million in clinical and regulatory milestones. For each milestone payment, Ipsen would receive a note convertible into Inspiration equity. The company states that assuming all milestones payments are made and the notes are converted into Inspiration equity, it could feasibly take on a 47% ownership of Inspiration’s equity on a fully diluted basis. Upon certain triggering events, Ipsen would also have the ability to acquire full control of Inspiration.

    Ipsen’s OBI-1 is in development for the treatment of patients with acquired hemophilia and hemophilia A who have developed an inhibitory immune reaction to human forms of factor VIII. Inspiration’s lead in-house hemophila product is a recombinant factor IX called IB1001 (rFIX) for hemophilia B. Both OBI-1 and IB1001 are expected to start Phase III trials this year.

    Inspiration also has earlier-stage candidates focused on both intravenous and noninvasive dosage forms of factor IX (hemophilia B), factor VIII (hemophilia A), and factor VIIa (hemophilia A&B). It is using its recombinant protein-manufacturing technologies to develop new, more efficacious, and cost-effective hemophila products. The company’s portfolio

    As a result of the alliance, global private equity firm Celtic Pharma, has converted both its direct interest in Inspiration’s IB1001 product and its equity interest in the company into a new class of preferred shares in Inspiration. Celtic says that this will give it a significant interest in the new enterprise.

    “OBI-1 makes sense to us as a strategic fit in our portfolio of products,” comments John Taylor, co-founder and chairman of Inspiration. “Not only does it add a valuable late-stage product to our pipeline, but it will benefit from our existing development infrastructure and future specialty sales force.”

    Jean-Luc Bélingard, chairman and CEO of Ipsen, adds, “Inspiration has both strong development experience and a broad pipeline that will provide the opportunity for new growth on our way to building a new, multiproduct global franchise for Ipsen in hematology. Subject to the products in development being approved by the relevant regulatory authorities and upon successful commercialization, we believe Inspiration’s portfolio including OBI-1 could exceed sales of $1 billion in the next 10 years.”


Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »